Gefitinib and dacomitinib, as EGFR inhibitors, were not effective in the EGFR-amplified GBM patients (NCT01520870, and NCT02447419),93,94 which may be caused by the low permeability of the blood–brain barrier. The gene discussed is EGFR; the disease is glioblastoma.